Search Results
Your search for Charles E. Geyer, Jr, MD, FACP,Charles E. Geyer, Jr, MD, FACP matches 6 pages
Showing 1 - 6
Charles E. Geyer, Jr, MD, FACP, on the SOFT Trial
Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by...
Charles E. Geyer, Jr, MD, FACP, on the NSABP B-36 Trial
Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses findings from abstract S3-02, “NSABP B-36: A randomized phase III trial comparing six cycles of fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with...
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, on Results from NSABP B-36 and SOFT Trials
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.
2015 ASCO Annual Meeting Planning Committees
The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with more than 28,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees, and thank them for their time and ...
Expert Point of View: Charles E. Geyer, Jr, MD, FACP
Discussant Charles E. Geyer, Jr, MD, FACP, Associate Director for Clinical Research at Virginia Commonwealth University Massey Cancer Center in Richmond, Virginia, singled out the power of this study’s dataset. “In 2002,” he said, “the Institute of Medicine named NSQIP [National Surgical Quality...
Expert Point of View: Charles E. Geyer, Jr, MD, FACP
Although the study clearly showed statistically significant differences, discussant Charles E. Geyer, Jr, MD, FACP, Associate Director of Clinical Research at the Massey Cancer Center in Richmond, Virginia, indicated that it’s unclear whether these are “clinically relevant differences,” adding...
